CL2013000027A1 - Compuestos derivados de (3-(4-(aminometil)fenoxi o feniltio)azetidin-1-il)(5-fenil-1,3,4-oxadiazol-2-il)metanona, antagonistas del receptor mch1; proceso para prepararlos; composicion farmaceutica; metodo de tratamiento; compuesto intermediario; y su uso para el tratamiento o profilaxis de la obesisdad. - Google Patents

Compuestos derivados de (3-(4-(aminometil)fenoxi o feniltio)azetidin-1-il)(5-fenil-1,3,4-oxadiazol-2-il)metanona, antagonistas del receptor mch1; proceso para prepararlos; composicion farmaceutica; metodo de tratamiento; compuesto intermediario; y su uso para el tratamiento o profilaxis de la obesisdad.

Info

Publication number
CL2013000027A1
CL2013000027A1 CL2013000027A CL2013000027A CL2013000027A1 CL 2013000027 A1 CL2013000027 A1 CL 2013000027A1 CL 2013000027 A CL2013000027 A CL 2013000027A CL 2013000027 A CL2013000027 A CL 2013000027A CL 2013000027 A1 CL2013000027 A1 CL 2013000027A1
Authority
CL
Chile
Prior art keywords
treatment
azetidin
methanone
oxadiazol
phenylthio
Prior art date
Application number
CL2013000027A
Other languages
English (en)
Inventor
Susanne Doris Margit Bokman-Winiwarter
Anders Carl Hogner
Lars Anders Mikael Johansson
Robert Andrew Judkins
Lanna Li
Bjorn Christian Ingvar Lofberg
Unge Per Oskar Sverker Von
Marlene Fredenwall
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44514822&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000027(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2013000027A1 publication Critical patent/CL2013000027A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compuestos derivados de (3-(4-(aminometil)fenoxi o feniltio)azetidin-1-il)(5-fenil-1,3,4-oxadiazol-2-il)metanona, antagonistas del receptor MCH1; proceso para prepararlos; composición farmacéutica; método de tratamiento; compuesto intermediario; y su uso para el tratamiento o profilaxis de la obesisdad.
CL2013000027A 2010-07-06 2013-01-03 Compuestos derivados de (3-(4-(aminometil)fenoxi o feniltio)azetidin-1-il)(5-fenil-1,3,4-oxadiazol-2-il)metanona, antagonistas del receptor mch1; proceso para prepararlos; composicion farmaceutica; metodo de tratamiento; compuesto intermediario; y su uso para el tratamiento o profilaxis de la obesisdad. CL2013000027A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36158510P 2010-07-06 2010-07-06

Publications (1)

Publication Number Publication Date
CL2013000027A1 true CL2013000027A1 (es) 2013-03-08

Family

ID=44514822

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000027A CL2013000027A1 (es) 2010-07-06 2013-01-03 Compuestos derivados de (3-(4-(aminometil)fenoxi o feniltio)azetidin-1-il)(5-fenil-1,3,4-oxadiazol-2-il)metanona, antagonistas del receptor mch1; proceso para prepararlos; composicion farmaceutica; metodo de tratamiento; compuesto intermediario; y su uso para el tratamiento o profilaxis de la obesisdad.

Country Status (26)

Country Link
US (1) US8546375B2 (es)
EP (1) EP2590969B1 (es)
JP (1) JP5827683B2 (es)
KR (1) KR20130041177A (es)
CN (1) CN103209979B (es)
AR (1) AR082113A1 (es)
AU (1) AU2011275547B2 (es)
BR (1) BR112013000296A2 (es)
CA (1) CA2802832A1 (es)
CL (1) CL2013000027A1 (es)
CR (1) CR20130005A (es)
CU (1) CU20130004A7 (es)
DO (1) DOP2013000004A (es)
EA (1) EA201291384A1 (es)
EC (1) ECSP13012369A (es)
ES (1) ES2527466T3 (es)
GT (1) GT201300006A (es)
MX (1) MX2012015102A (es)
NI (1) NI201200196A (es)
PE (1) PE20130781A1 (es)
PH (1) PH12013500027A1 (es)
SA (1) SA111320581B1 (es)
SG (1) SG186275A1 (es)
TW (1) TW201206916A (es)
UY (1) UY33487A (es)
WO (1) WO2012004588A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
CN104974106B (zh) * 2014-04-04 2019-02-22 浙江普洛康裕制药有限公司 5-烷基-[1,3,4]-噁二唑-2-甲酸烷基酯的合成方法
CN108840812B (zh) * 2018-06-29 2020-08-18 南京富润凯德生物医药有限公司 一种3-(二氟甲基)-3-羟基氮杂环丁烷中间体及其盐的制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4212867A (en) * 1977-03-03 1980-07-15 Philagro 2-Cyano-5-substituted 1,3,4-oxadiazoles and fungicidal compositions containing them
DE3039087A1 (de) 1980-10-16 1982-05-19 Hoechst Ag, 6000 Frankfurt 1-(1,3-dioxolan-2-ylmethyl)-azole, ihre salze, verfahren zu ihrer herstellung und ihre verwendung
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB2184122B (en) 1985-12-17 1989-10-18 Boots Co Plc N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
CA2126976A1 (en) 1991-12-31 1993-07-08 Hisashi Takasugi Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
WO1997005131A1 (en) 1995-08-02 1997-02-13 J. Uriach & Cia. S.A. New carboxamides with antifungal activity
SE0202134D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
EP1553089B1 (en) 2002-07-30 2009-09-30 Banyu Pharmaceutical Co., Ltd. Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
EP1593667A4 (en) 2003-02-12 2009-03-04 Takeda Pharmaceutical Amine derivative
US20060293298A1 (en) 2003-04-10 2006-12-28 Bamford Mark J Compounds
GB0400193D0 (en) 2004-01-07 2004-02-11 Astrazeneca Ab Therapeutic agents
US20070185079A1 (en) 2004-01-07 2007-08-09 Astrazeneca Ab Therapeutic agents I
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
TW200538098A (en) 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
DK1786790T3 (da) 2004-07-26 2009-07-20 Lilly Co Eli Oxazolderivater som histamin H3 receptorstoffer, fremstilling og terapeutiske anvendelser
WO2006044228A1 (en) 2004-10-18 2006-04-27 Eli Lilly And Company Histamine h3 receptor inhibitors, preparation and therapeutic uses
JP4988591B2 (ja) 2004-12-17 2012-08-01 イーライ リリー アンド カンパニー 新規なｍｃｈ受容体アンタゴニスト
AR051802A1 (es) 2004-12-21 2007-02-07 Astrazeneca Ab Heterociclos antagonistas de mchr1
JP2006176443A (ja) 2004-12-22 2006-07-06 Shionogi & Co Ltd メラニン凝集ホルモン受容体アンタゴニスト
CA2610671A1 (en) 2005-05-31 2006-12-07 Astrazeneca Ab Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
ATE488496T1 (de) 2005-06-22 2010-12-15 Pfizer Prod Inc Histamin-3-rezeptorantagonisten
US20080221107A1 (en) 2005-07-15 2008-09-11 Astrazeneca Ab Therapeutic Agents
EP1973905A4 (en) 2006-01-06 2010-12-08 Astrazeneca Ab COMPOUNDS
EP2051977A2 (en) 2006-07-20 2009-04-29 Amgen Inc. SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1
JP2010501553A (ja) 2006-08-18 2010-01-21 アストラゼネカ アクチボラグ Ｍｃｈｒ１アンタゴニストとしてのチエノピリミジン−４−オン誘導体およびチエノピリダジン−７−オン誘導体
ES2483866T3 (es) 2006-12-05 2014-08-08 Janssen Pharmaceutica Nv Derivados de diaza-espiro-piridinona sustituidos novedosos para uso en enfermedades mediadas por MCH-1
WO2008076562A1 (en) * 2006-12-14 2008-06-26 Eli Lilly And Company 5- [4- (azetidin-3-yl0xy) -phenyl] -2-phenyl-5h-thiaz0l0 [5,4-c] pyridin-4-0ne derivatives and their use as mch receptor antagonists
EP2148931A2 (en) 2007-04-17 2010-02-03 Vertex Pharmaceuticals Incorporated Drug discovery methods for aurora kinase inhibitors
WO2009018415A1 (en) 2007-07-31 2009-02-05 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
AU2008290634B2 (en) 2007-08-22 2012-12-06 F. Hoffmann-La Roche Ag Pyrrolidine aryl-ether as NK3 receptor antagonists
DK2212283T3 (da) * 2007-10-17 2011-12-19 Sanofi Sa Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf
US8124636B2 (en) 2008-04-30 2012-02-28 Hoffmann-La Roche Inc. Imidazolidinone derivatives as 11B-HSD1 inhibitors
CA2721303C (en) * 2008-05-08 2016-06-28 Evotec Ag Azetidines and cyclobutanes as histamine h3 receptor antagonists
SA110310332B1 (ar) * 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
US9006232B2 (en) 2009-08-13 2015-04-14 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives
US9051296B2 (en) * 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers

Also Published As

Publication number Publication date
EP2590969A2 (en) 2013-05-15
UY33487A (es) 2012-02-29
WO2012004588A2 (en) 2012-01-12
CR20130005A (es) 2013-04-17
TW201206916A (en) 2012-02-16
GT201300006A (es) 2014-11-06
EA201291384A1 (ru) 2013-07-30
MX2012015102A (es) 2013-05-01
DOP2013000004A (es) 2013-04-30
NI201200196A (es) 2013-10-16
CU20130004A7 (es) 2013-05-31
WO2012004588A3 (en) 2012-08-09
ECSP13012369A (es) 2013-01-31
ES2527466T3 (es) 2015-01-26
US20120010189A1 (en) 2012-01-12
KR20130041177A (ko) 2013-04-24
JP2013535413A (ja) 2013-09-12
EP2590969B1 (en) 2014-10-15
AU2011275547A1 (en) 2013-02-07
PE20130781A1 (es) 2013-07-20
HK1182712A1 (en) 2013-12-06
AR082113A1 (es) 2012-11-14
PH12013500027A1 (en) 2017-10-25
AU2011275547B2 (en) 2015-10-29
BR112013000296A2 (pt) 2019-09-24
CA2802832A1 (en) 2012-01-12
SA111320581B1 (ar) 2014-06-17
JP5827683B2 (ja) 2015-12-02
CN103209979B (zh) 2016-02-10
US8546375B2 (en) 2013-10-01
CN103209979A (zh) 2013-07-17
SG186275A1 (en) 2013-01-30

Similar Documents

Publication Publication Date Title
BR112014012878A8 (pt) composto, uso de um composto, composição farmacêutica e processos de fabricação de um composto
ECSP14013325A (es) Piridopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr)
GT201400111A (es) Triazolopiridinas sustituidas
NZ746950A (en) Heterocyclic gpr119 agonist compounds
CL2009000873A1 (es) Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b
MX388682B (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
PH12015502524A1 (en) New somatostatin receptor subtype 4 (sstr4) agonists
CL2009000171A1 (es) Compuestos derivados de 1-oxa-3-azaespiro, antagonistas del receptor y5 de neuropeptido y (npy); composicion farmaceutica que comprende dicho compuesto; y uso para el tratamiento de trastornos de la alimentacion, trastornos de la bebida, obesidad y depresion.
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
EA201071291A3 (ru) Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств
BR112013008501A2 (pt) métodos para o tratamento de psoríase usando anatgonistas de il-17
PA8784001A1 (es) Oxazolidinonas sustituidas y su uso
MX2012002366A (es) Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
CL2015001536A1 (es) Compuestos derivados de piridina, agonistas del receptor de canabinoides 2; proceso de sintesis; su uso para el tratamiento o profilaxis del dolor, aterosclerosis, retinopatia diabetica, infarto de miocardio, apoplejia, entre otras.
DOP2012000006A (es) Agonista de gpr119
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
ATE557023T1 (de) Piperidinylverbindungen als gpcr-agonisten
MX2009009153A (es) Pirano-pirazol-aminas.
CL2011002965A1 (es) Compuestos derivados de piperidinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso de dichos compuestos para el tratamiento y/o profilaxis de trastornos cardiovasculares, tromboembolicos y/o tumores.
UY31133A1 (es) "oxazolidinonas sustituidas y su uso"
MY176521A (en) Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising the same and use thereof
UA117154C2 (uk) Антагоністи s1p3
AU2011279845A8 (en) Novel pyrrolidine derived beta 3 adrenergic receptor agonists
CL2008002696A1 (es) Compuestos derivados de hidroxi-benzamidas, antagonistas de receptores muscarinicos; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica; y uso del compuesto para el tratamiento de enfermedades de las vias respiratorias obstructivas o inflamatorias, broncoconstriccion, asma, bronquitis.